• Je něco špatně v tomto záznamu ?

The contribution of cerebrovascular risk factors, metabolic and inflammatory changes to cognitive decline in Parkinson's disease: preliminary observations

B. Veselý, E. Koriťáková, NI. Bohnen, D. Viszlayová, S. Királová, P. Valkovič, E. Kurča, I. Rektor,

. 2019 ; 126 (10) : 1303-1312. [pub] 20190722

Jazyk angličtina Země Rakousko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025620

Grantová podpora
I01 RX001631 RRD VA - United States
P01 NS015655 NINDS NIH HHS - United States
P50 NS091856 NINDS NIH HHS - United States
NV16-33798A MZ0 CEP - Centrální evidence projektů

To determine whether systemic medical factors, such as vascular risk factors, metabolic and inflammatory markers contribute to cognitive decline in Parkinson's disease (PD); if confirmed to determine whether a clinically applicable risk factor model can predict the conversion from normal cognition (NC) to mild cognitive impairment (MCI). 58 patients who met the UK Brain Bank Criteria for PD underwent clinical and laboratory assessment at study entry; 47 patients were re-assessed after 2 years. Medical history, vascular risk (QRISK2), blood metabolic and inflammatory factors, brain vessel examinations, activity of daily living, and neuropsychological testing were performed. Forty patients had NC and 18 patients had MCI at baseline. Patients with MCI had higher level of interleukin 6, folic acid below normal range and higher L-dopa equivalent dose compared to cognitive normal patients at baseline. Patients with NC at baseline were classified into two groups: patients who remained cognitively normal (non-converters, n = 23) and patients who progressed to MCI (converters, n = 11). MCI converters were older at baseline and had higher QRISK2 than the non-converters. Patients with higher QRISK2, lower uric acid level and lower activity of daily living scale at baseline had a higher risk of converting from NC to MCI with a sensitivity of 72.2%, a specificity of 87%, and an overall accuracy of 82.4%. Systemic medical factors are associated with cognitive impairment in PD both cross-sectionally and longitudinally. A risk factor model predicting the decline from NC to MCI could be constructed.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025620
003      
CZ-PrNML
005      
20201222160314.0
007      
ta
008      
201125s2019 au f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00702-019-02043-7 $2 doi
035    __
$a (PubMed)31332506
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a au
100    1_
$a Veselý, Branislav $u Department of Neurology, Faculty Hospital, Constantine the Philosopher University, Nitra, Slovak Republic. Central European Institute of Technology (CEITEC), Brain and Mind Research Program, Masaryk University, Pekařská 664/53, 656 91, Brno, Czech Republic.
245    14
$a The contribution of cerebrovascular risk factors, metabolic and inflammatory changes to cognitive decline in Parkinson's disease: preliminary observations / $c B. Veselý, E. Koriťáková, NI. Bohnen, D. Viszlayová, S. Királová, P. Valkovič, E. Kurča, I. Rektor,
520    9_
$a To determine whether systemic medical factors, such as vascular risk factors, metabolic and inflammatory markers contribute to cognitive decline in Parkinson's disease (PD); if confirmed to determine whether a clinically applicable risk factor model can predict the conversion from normal cognition (NC) to mild cognitive impairment (MCI). 58 patients who met the UK Brain Bank Criteria for PD underwent clinical and laboratory assessment at study entry; 47 patients were re-assessed after 2 years. Medical history, vascular risk (QRISK2), blood metabolic and inflammatory factors, brain vessel examinations, activity of daily living, and neuropsychological testing were performed. Forty patients had NC and 18 patients had MCI at baseline. Patients with MCI had higher level of interleukin 6, folic acid below normal range and higher L-dopa equivalent dose compared to cognitive normal patients at baseline. Patients with NC at baseline were classified into two groups: patients who remained cognitively normal (non-converters, n = 23) and patients who progressed to MCI (converters, n = 11). MCI converters were older at baseline and had higher QRISK2 than the non-converters. Patients with higher QRISK2, lower uric acid level and lower activity of daily living scale at baseline had a higher risk of converting from NC to MCI with a sensitivity of 72.2%, a specificity of 87%, and an overall accuracy of 82.4%. Systemic medical factors are associated with cognitive impairment in PD both cross-sectionally and longitudinally. A risk factor model predicting the decline from NC to MCI could be constructed.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a cerebrovaskulární poruchy $x diagnóza $x epidemiologie $x metabolismus $7 D002561
650    _2
$a kognitivní dysfunkce $x diagnóza $x epidemiologie $x metabolismus $7 D060825
650    _2
$a kohortové studie $7 D015331
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a mediátory zánětu $x metabolismus $7 D018836
650    _2
$a longitudinální studie $7 D008137
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a metabolické nemoci $x diagnóza $x epidemiologie $x metabolismus $7 D008659
650    _2
$a lidé středního věku $7 D008875
650    _2
$a Parkinsonova nemoc $x diagnóza $x epidemiologie $x metabolismus $7 D010300
650    _2
$a rizikové faktory $7 D012307
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Koriťáková, Eva $u Central European Institute of Technology (CEITEC), Brain and Mind Research Program, Masaryk University, Pekařská 664/53, 656 91, Brno, Czech Republic. Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Bohnen, Nicolaas I $u Departments of Radiology and Neurology, University of Michigan, and Ann Arbor VA Medical Center, Ann Arbor, MI, USA.
700    1_
$a Viszlayová, Daša $u Department of Neurology, Charles University, Faculty of Medicine, Hradec Králové, Czech Republic.
700    1_
$a Királová, Silvia $u Department of Clinical Psychology, Faculty Hospital, Constantine Philosopher University, Nitra, Slovak Republic.
700    1_
$a Valkovič, Peter $u Second Department of Neurology, Comenius University School of Medicine, Bratislava, Slovak Republic.
700    1_
$a Kurča, Egon $u Clinic of Neurology, Comenius University, Jessenius Faculty of Medicine, Martin, Slovak Republic.
700    1_
$a Rektor, Ivan $u Central European Institute of Technology (CEITEC), Brain and Mind Research Program, Masaryk University, Pekařská 664/53, 656 91, Brno, Czech Republic. irektor@med.muni.cz.
773    0_
$w MED00010058 $t Journal of neural transmission (Vienna, Austria : 1996) $x 1435-1463 $g Roč. 126, č. 10 (2019), s. 1303-1312
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31332506 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222160310 $b ABA008
999    __
$a ok $b bmc $g 1599765 $s 1116306
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 126 $c 10 $d 1303-1312 $e 20190722 $i 1435-1463 $m Journal of neural transmission $n J Neural Transm $x MED00010058
GRA    __
$a I01 RX001631 $p RRD VA $2 United States
GRA    __
$a P01 NS015655 $p NINDS NIH HHS $2 United States
GRA    __
$a P50 NS091856 $p NINDS NIH HHS $2 United States
GRA    __
$a NV16-33798A $p MZ0
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace